Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19819284 | 1.00 | GNPAT (0.43) | GNPATRENECE1ERAP2LNPEP | |
| SCHEMBL31374694 | 0.83 | ECE1 (0.46) | GNPATECE1ERAP2LNPEPACE | |
| SCHEMBL7497331 | 0.80 | ATM (0.41) | RENACECTSSCTSKCTSL | |
| SCHEMBL19815042 | 0.80 | ATM (0.41) | RENACECTSSCTSKCTSL | |
| SCHEMBL19814966 | 0.80 | ATM (0.41) | RENACECTSSCTSKCTSL | |
| SCHEMBL6442123 | 0.77 | ITGA4 (0.46) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL31440712 | 0.75 | GNPAT (0.52) | GNPATRENECE1ERAP2LNPEP | |
| SCHEMBL3789929 | 0.75 | CTSS (0.59) | GNPATRENECE1ACECTSS | |
| SCHEMBL29839818 | 0.75 | CTSS (0.59) | GNPATRENECE1ACECTSS | |
| SCHEMBL3789933 | 0.75 | CTSS (0.59) | GNPATRENECE1ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3491005-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020358-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | C3AR1, C5AR1, C5AR2 | GNPAT 3252/4885REN 503/4885ECE1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.